Marc Elia
Chairman presso INVIVYD, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Marc W.
Elia is the founder of Nivalis Therapeutics, Inc. (founded in 2007) and M28 Capital Management LP (founded in 2012).
He currently holds the position of Chairman at Invivyd, Inc. (since 2022), Independent Director at SQZ Biotechnologies Co. (since 2018), and Independent Director at Fractyl Health, Inc. (since 2021).
In the past, he worked as a Director at Adimab LLC and held positions as an Analyst and Partner at Bridger Management LLC and Bridger Capital LLC respectively (from 2012 to 2019).
Mr. Elia completed his undergraduate degree at Carleton College in 1998.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Marc Elia
| Società | Posizione | Inizio |
|---|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Director/Board Member | 09/08/2018 |
| FRACTYL HEALTH, INC. | Director/Board Member | 16/06/2021 |
| INVIVYD, INC. | Chairman | 01/07/2022 |
M28 Capital Management LP
 M28 Capital Management LP Investment ManagersFinance M28 Capital Management LP (M28 Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Stamford, Connecticut. The firm was founded by Marc Elia in 2019. M28 Capital provides investment advisory services on a discretionary basis to several private fund clients. | Founder | 01/08/2012 |
Precedenti posizioni note di Marc Elia
| Società | Posizione | Fine |
|---|---|---|
Bridger Management LLC
 Bridger Management LLC Investment ManagersFinance Bridger Management LLC (Bridger) is a registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Roberto Mignone in 2000 and is a direct subsidiary of Bridger Management II LP. Bridger serves as the investment adviser, with discretionary trading authority, to private, pooled investment vehicles, the securities of which are offered through a private placement memorandum to accredited investors. | Analyst-Equity | 01/09/2019 |
| Bridger Capital LLC | Corporate Officer/Principal | 01/09/2019 |
Adimab LLC
 Adimab LLC BiotechnologyHealth Technology Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH. | Director/Board Member | - |
Nivalis Therapeutics, Inc.
 Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Founder | - |
Formazione di Marc Elia
| Carleton College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| FRACTYL HEALTH, INC. | Health Technology |
| INVIVYD, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
Bridger Management LLC
Bridger Management LLC Investment ManagersFinance Bridger Management LLC (Bridger) is a registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Roberto Mignone in 2000 and is a direct subsidiary of Bridger Management II LP. Bridger serves as the investment adviser, with discretionary trading authority, to private, pooled investment vehicles, the securities of which are offered through a private placement memorandum to accredited investors. | Finance |
Adimab LLC
Adimab LLC BiotechnologyHealth Technology Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH. | Health Technology |
| Bridger Capital LLC | |
M28 Capital Management LP
M28 Capital Management LP Investment ManagersFinance M28 Capital Management LP (M28 Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Stamford, Connecticut. The firm was founded by Marc Elia in 2019. M28 Capital provides investment advisory services on a discretionary basis to several private fund clients. | Finance |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |
- Borsa valori
- Insiders
- Marc Elia
